17/06/2008 14:50. LONDON, Jun 16, 2008 (Thomson Financial via COMTEX) -- TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries Ltd. said ADAGIO, the phase III study has shown that AZILECT 1 mg tablets can slow down the progression of Parkinson's disease.

In a statement, the company said the drug could potentially become the first disease modifying treatment for Parkinson's.

In the trial, the currently marketed AZILECT 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical... // Trading Markets

Total: 2 news articles
First News Article: Hemscott, 16/06/2008 18:06